Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Venous Thromboembolism Treatment Market

Venous Thromboembolism Treatment Market Analysis

  • Report ID: GMI3929
  • Published Date: Apr 2021
  • Report Format: PDF

Venous Thromboembolism Treatment Market Analysis

Compression system segment in the venous thromboembolism treatment market accounted for more than USD 120 million in 2020. Increasing number of surgical procedures has spurred the adoption of compression devices for DVT prophylaxis. Surgeries including orthopedic procedures cause long duration of immobility and thus, there is higher probability of development of DVT. Hence, patients are recommended to use compression devices post-procedure to curb the risk.

 

Venous thromboembolism treatment market for Pulmonary embolism segment is projected to witness a 9.4% growth rate by 2027. PE is life-threatening and the 3rd most commonly affected CVD. Hence, market players are launching novel devices including ultrasound-guided catheter-directed thrombolysis systems to cater to need for effective treatment. Thus, with rising need for disease management, the demand for pulmonary embolism treatment devices will expand over the coming years.
 

Hospitals end-use segment dominated around 75% of the venous thromboembolism treatment market share in 2020. Large number of surgical procedures and interventions carried out in hospitals boosts the demand for VTE prophylactic devices in these settings.
 

Hospitals have well-developed infrastructure and thereby, large base of patient admissions. Wide range of ailments including cancer are treated in hospitals and hence due to associated risk of VTE, these settings showcase higher demand for various VTE treatment products. In addition, growing prevalence of hospital-associated venous thromboembolism will further stimulate the market progression during the forecast period.
 

North America venous thromboembolism treatment market captured over 40% of revenue share in 2020. As per the American Medical Association, around 2 million Americans are affected by deep vein thrombosis annually. Thus, with increasing incidence of such fatal disease, its awareness, diagnosis and timely therapy is crucial.
 

Several organizations are taking initiatives to raise awareness about VTE in the country. Some organizations, in collaboration with the CDC, are joining the ‘Stop the Clot, Spread the Word’ campaign to spread national awareness about blood clots. Such initiatives will positively impact knowledge about disease diagnosis and treatment alternatives, thereby influencing the market value during the forecast timeline.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The revenue share of the venous thromboembolism treatment industry was valued at USD 950 million in 2020 and will rise at a CAGR of over 8.7% up to 2027 with a higher prevalence of cardiovascular diseases (CVD) and cancer.

The market size from the compression system device segment reached USD 120 million in 2020 and will grow with increasing adoption across DVT prophylaxis.

The market revenue from pulmonary embolism applications is expected to observe a growth rate of 9.4% up to 2027 due to the increasing prevalence of the disease.

Hospitals accounted for over 75% of total revenue share in 2020 and will see higher expansion owing to the increase in the number of surgical procedures that require VTE prophylactic devices.

North America was responsible for over 40% of the venous thromboembolism treatment revenue share in 2020 due to the rise in the number of initiatives in the region.

Venous Thromboembolism Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2020
  • Companies covered: 7
  • Tables & Figures: 192
  • Countries covered: 18
  • Pages: 120
 Download Free Sample